Semaglutide Weight Management and Cardiovascular Risk Reduction

Commercial execution Purpose and sustainability (ESG) Strategic Aspirations 2025 | Highlights first three months 2023 Progress towards zero environmental impact Carbon emissions decreased by 21% vs Q1 20191 Adding value to society Medical treatment provided to 37.2 million people living with diabetes Reaching more than 42,000 children in Changing Diabetes in Children programme Being recognised as a sustainable employer Share of women in senior leadership positions has increased to 39% from 37% end of March 2022 ピ Diabetes value market share increased by 1.7%-points to 32.2%2 Obesity care sales of DKK 7.8 billion (+124% at CER) Rare disease sales of DKK 4.6 billion (-16% at CER) IIIIIO Innovation and therapeutic focus • • Further raise innovation bar for Diabetes treatment Regulatory submission of once-weekly insulin icodec Completion of phase 3 trial PIONEER PLUS Completion of phase 1/2 trials with GLP-1/GIP Develop superior treatment solutions for obesity Phase 3a trials REDEFINE 2 & 3 initiated with CagriSema Strengthen and progress Rare Disease pipeline . • • . Somapacitan approved in the US for GHD in children CRL received for concizumab in the US Establish presence in Other serious chronic diseases Phase 1 trials initiated with cell therapy treatment 1Scope 1,2 and partial scope 3 limited to CO2 emissions from business flights and product distribution; 2MAT (Moving annual total) value market share VP: Vice president; CER: Constant exchange rates; CRL: Complete Response Letter; US: United States; GHD: Growth Hormone Deficiency; GIP: Gastric inhibitory polypeptide; GLP-1: Glucagon Like Peptide 1 Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth Financials Sales growth of 25% (CER) and operating profit growth of 28% (CER) Operational leverage reflecting sales growth Free cash flow of DKK 24.8 billion and DKK 23.5 billion returned to shareholders

View entire presentation